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A characteristic feature of chronic wounds is a prolonged inflammatory response 
as well as susceptibility to infection. Studies have shown that during the inflammatory 
response, there is a significant increase in the levels of neutrophil-derived enzymes. The 
purpose of this work was to determine whether the anionic macromolecule polystyrene 
sulfonate (PSS) and five of its salt forms, namely PSS-calcium, PSS-chlorhexidine, PSS-
doxycycline, PSS-glutathione and PSS-silver are able to inhibit the activity of three of the 
enzymes whose levels are elevated in chronic wounds: elastase, cathepsin G and 
myeloperoxidase.  
 In addition to the enzyme inhibition study, the various formulations’ antimicrobial 
properties were analyzed by evaluating their ability to inhibit the growth of three 
common clinical isolates: Staphylococcus aureus, Pseudomonas aeruginosa and 
Acinetobacter baumanii. It is worthy to note that the structure of PSS makes it a very 
flexible platform to which other molecules can be added in order to address a variety of 
“targets” as well as tailor quantitative strength.     
x 
 
 The results from this project showed that purified PSS and the various salt 
derivatives were able to inhibit elastase and cathepsin G activity. In addition, three of the 
therapeutic cations attached to PSS: silver, doxycycline and chlorhexidine retained their 
intrinsic antimicrobial properties without having an adverse effect on healthy tissue. In 
summary, this study demonstrated that PSS possessed an intrinsic ability to inhibit a 
number of proteases and that it could also be used as a delivery vehicle for other 
compounds with potential therapeutic value.  
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Introduction 
 
Phases of Wound Healing 
The skin is the largest and one of the most complex organs in the body and damage to it is 
an inevitable occurrence. Therefore, it is imperative that the skin has evolved mechanisms that 
allow it to repair itself and restore functionality to the injured area in a timely manner.  Although 
some of the key components of wound healing have been worked out, there is still a great deal to 
be learnt about this inherently complex process. To that end, the management and treatment of 
complex wounds is often viewed as an art and not necessarily a science since healthcare 
professionals often have to rely on their past experiences and intuition in order to plan the right 
approach to dealing with a specific wound. Prior work has shown that this restorative phenomena 
occurs in four overlapping stages that can take several days or years to complete, depending on 
the severity and complexity of the injury.  
 
Hemostasis 
The first phase in wound healing is hemostasis which is then followed by inflammation, 
tissue formation and remodeling.  During wounding, in addition to the dermis, the blood vessels 
and tissue underlying the outermost layer of the skin are also damaged. This results in bleeding 
at the site that needs to be controlled and ultimately stopped.  In order to achieve this, there is 
instantaneous and transient vasoconstriction of the blood vessels at the site of the injury followed 
by the formation of a plug in the form a clot. Clots are formed because blood platelets that are 
usually contained within the lumen of the blood vessels become exposed to tissue in the 
extracellular matrix causing them to aggregate at the site of hemorrhage (Esmon 1993). After the 
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bleeding has been controlled, the blood vessels vasodilate and develop gaps in the capillaries 
(Hynes 1992). The presence of these gaps allow plasma as well as the migrating leukocytes to 
enter the extravascular space causing edema, a characteristic feature of this stage in the healing 
process (McLean et al. 1964). 
The clot is a multifunctional component because it not only stops the flow of blood, but 
upon the completion of its formation fibrin, an end product of coagulation is released. Fibrin lays 
down the foundational matrix in the wound which is later covered with vitronectin and 
fibronectin.  Fibronectin is produced by surrounding fibroblast and epithelial cells and is integral 
in providing the framework to which migrating cells can attach to so that they can make their 
way to the wound (Clark et al. 1985; Grinnell 1984). In addition, degranulation of the platelets in 
the clot releases cytokines and a wide variety of growth factors including PDGF and TGF-β that 
recruit other cells such as neutrophils and macrophages to the wound site thereby initiating the 
second phase of healing– inflammation (Clark 2001).  
 
Inflammation 
Inflammation can be defined as “the breakdown of preexisting tissue scaffolding and 
cleanup of cellular, extracellular, and pathogen debris.” (Van Der Veen et al. 2009). Neutrophilic 
migration help establish the infamous hallmarks of inflammation – erythema, pain, swelling and 
heat. Under normal conditions, leukocytes are not present in tissue, however, immediately after 
trauma, the endothelial cells at the site begin to express P-selectin and E-selectin which 
facilitates the tethering and subsequent adhesion of local leukocytes specifically neutrophils. 
Once they have adhered to the endothelial cell surface via their respective receptors, they are 
primed making it possible for them to cross the endothelial barrier. When in the tissue, they can 
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bind to the fibrin-fibronectin-vectronectin matrix using their membrane receptors in order to 
arrive at the site of injury (Hsieh et al. 1983; Hynes 1992).    
 Neutrophils, which are also known as polymorphonuclear leukocytes (PMN), are the 
most abundant circulating leukocyte.  The concentration of neutrophils in the blood of healthy 
humans ranges from 3 to 6 million cells per ml but can increase to 15–40 million per ml in 
individuals with an infection (Li et al., 2002).  Neutrophils constitute the ''first line of defense'' 
against infectious agents or ''nonself'' substances that penetrate the body's physical barriers. Once 
an inflammatory response is initiated, neutrophils are the first cells to be recruited to sites of 
infection or injury. Their targets include bacteria, fungi, protozoa, viruses, virally infected cells, 
tumour cells, and devitalized tissue. They develop in the bone marrow.  Mature neutrophils 
contain cytoplasmic granules (primary or azurophil and secondary or specific) and a lobulated 
chromatin-dense nucleus with no nucleolus. 
Neutrophils are professional phagocytes, they utilize a combination of degradative 
enzymes that are contained in their granules and a robust respiratory burst to neutralize ingested 
pathogens.  During phagocytosis, cytosolic granules (lysosomes) fuse with the invaginating 
plasma membrane (around the engulfing microorganism) to form a phagolysosome into which 
they release their contents, thereby creating a highly toxic microenvironment.  It is at this step 
that the contents of the granules and products of the respiratory burst come together to act on 
ingested microbes.  This degranulation normally prevents release of the toxic components into 
the extracellular milieu.  However, some target may be too large to be fully phagocytosed or they 
avoid engulfment, resulting in frustrated phagocytosis in which no phagosome is formed. These 
may be killed extracellularly. However, tissue damage occurs when neutrophil microbicidal 
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products are released extracellularly to such an extent that host defences (antioxidant and 
antiprotease screens) in the immediate vicinity are overwhelmed.   
The reactive oxygen species produced as a result of the activated NADPH complex’s 
respiratory burst aid in the killing of microbes.  The initial product of the respiratory burst is the 
relatively unreactive molecule superoxide (·O2) .  However, this molecule can be utilized by a 
number of pathways to generate far more reactive reactive oxygen species including hydrogen 
peroxide (by dismutation), hydroxyl radical (·OH), singlet oxygen, and peroxynitrite (ONO2−) by 
reacting with nitric oxide.   In neutrophils, using hydrogen peroxide as a substrate, 
myeloperoxidase can produce hypochlorous acid (Nathan 2002).  
 After phagocytizing the damaged tissue and the microbes, neutrophils undergo apoptosis 
and are in turn phagocytized by macrophages that have begun to invade the site. Macrophages 
appear at the site 48 to 96 hours after the initial injury and like the neutrophils, they contribute to 
the wound’s debridement, phagocytize the apoptotic neutrophils, continue pathogen killing and 
release growth factors such as PDGF, TGF-β and FGF which serve to regulate the wound healing 
process (Adams et al. 1984; Goldman 2004). Activation of the macrophages is an important step 
in ensuring the wound progresses to the next stage and is not stalled in the inflammatory stage. 
Prior studies have shown that if these growth factors are not present or their expression is 
reduced, the healing process is significantly impaired and many of the wounds are unable to 
progress through the other phases of healing and subsequently become acute (Cooper et al. 
1994).  
It is worthy to note that although the macrophages are a key component in destroying the 
microbes that the neutrophils were unable to destroy, the mechanism via which they fulfill this 
task is slightly different. Although there is some controversy regarding the exact mechanism 
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involved, the vast majority of researchers seem to agree on the fact that the macrophages 
involved make a large amount of nitric oxide. The nitric oxide that is synthesized then reacts 
with peroxide ion oxygen radicals that give rise to an even more potent toxin in the form of 
peroxynitrite and hydroxyl radicals (Beckman et al. 1990). This lethal combination is usually 
sufficient to rid the wound of any bacteria that was not previously cleared by neutrophilic 
activity. 
 
Tissue Formation and Remodeling 
 The inflammatory process does not continue indefinitely but it is regulated by proteins 
such as PGE2 that shuts down the inflammatory response thereby promoting the proliferative or 
tissue forming phase (Nathan 2002). In the restorative phase, keratinocytes and mesenchymal 
cells proliferate, migrate and differentiate so that the provisional matrix formed by the fibrin-
vectronectin-fibronectin during hemostasis can be replaced by a more permanent scaffold in the 
form of fibrillar collagens and proteoglycans thereby restoring the integrity of the injured region 
(Nwomeh 1998). Furthermore, epithelial cells proliferate in an attempt to repair the damaged 
blood vessels, re-establish the vascular network, prevent fluid loss and further bacterial infection 
(Broughton 2006). The epithelial cells are able to form new vessels after they have been 
stimulated by the growth factor VEGF which is secreted primarily by keratinocytes. It is worthy 
to note that macrophages, fibroblasts, platelets and neighboring endothelial cells are also able to 
contribute to angiogenesis (Gospodarowicz et al.1989; Folkman et al. 1992). 
Another pair of important growth factors involved in this phase of healing is PDGF and 
EGF (Lawrence 1998). They are secreted from platelets, macrophages and are responsible for 
recruiting fibroblasts to the wound site. Once the fibroblasts arrive, the presence of the 
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aforementioned growth factors causes them to synthesize a temporary matrix composed of 
collagen III, glycosaminoglycans and fibronectin. In addition to the re-establishing the 
connective tissue, the integrity of the epithelium has to be restored so that the individual can be 
protected from further invasion of microbes and other foreign substances. Epithelialization is 
also closely regulated by growth factors namely growth factor-α, epidermal growth factor and 
keratinocyte growth factor (Nanney et al. 1996). These growth factors are responsible for 
activating the epidermal cells that would allow them to migrate to the dermis.  
 At this point, the injured region has regained most of its normalcy and the remodeling 
phase begins in an attempt to fine tune the structure of the extracellular matrix and optimize the 
strength of the skin. Even in optimal conditions, the strength of the scar never reaches that of 
normal skin, however approximately 80% of the skin’s strength is regained after 6 months 
(Grinnel 1984).   
 
Chronic Wounds 
 Although the wound healing process is a well orchestrated series of mechanisms that 
involves a host of proteases, growth factors and enzymes, whose coordinated appearance at the 
site of injury restores functionality and integrity, if it is not allowed to progress through the 
various stages in a timely manner the healing process can be delayed indefinitely. This delayed 
healing predisposes the wound to becoming acute and eventually chronic. Previous studies have 
shown that one of the hallmarks of chronic wounds is elevated levels of neutrophils which 
ultimately lead to an increase in proteolytic and degradative enzymes that arrest the wound in the 
inflammatory phase (Yager et al. 1999). There have been several neutrophilic proteases and 
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enzymes that have been identified as key players in perpetuating the inflammatory phase 
specifically elastase, cathepsin G, myeloperoxidase and a host of MMPs.  
 Elastase is one of the many cationic serine proteases whose level is frequently elevated in 
chronic wounds and is responsible for the degrading peptide growth factors and fibronectin: one 
of the proteins involved in the re-construction of the extracellular matrix. Cathepsin G, another 
serine protease has also been shown to destroy extracellular matrix (Chen, et al. 1997; Grinnell et 
al. 1996; Hennrick et al. 1997). They both usually cleave their substrate at a valine or alanine 
residue which is characteristic of most serine proteases. As previously mentioned, under normal 
circumstances these proteases are important in removing damaged tissue and eliminating 
pathogens after injury, however because their levels are elevated in chronic wounds, they can 
bind and cleave healthy tissue. Elastase and cathepsin G are of particular concern because of 
their broad specificity and subsequent destruction of a wide variety of extracellular matrix 
components, soluble growth factors and cell surface proteins.  
Myleoperoxidase is another neutrophilic enzyme whose levels are elevated in chronic 
wounds. During the normal immune response, interacts with its substrates hydrogen peroxide 
and a halide and together they form a ‘powerful antimicrobial system (Van Der Veen et al. 
2009). At high concentrations, the MPO-derived oxidants have been implicated in tissue injury. 
For example, cartilage erosion in rheumatoid arthritis is a result of the activity of activated 
neutrophils specifically the myeloperoxidase (Schiller 2003). 
Chronic wounds are not only problematic to healthcare providers but it is a growing 
socioeconomic burden that translates into approximately 25 billion dollars spent a year on their 
treatment (Sen et al. 2009). Although it is possible for an injury resulting in the breaking of the 
skin to progress to a chronic wound, it is possible for them to form as result of leg, pressure and 
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diabetic ulcers. Leg ulcers are a common condition among persons who have lower limb arterial 
or venous insufficiency. Individuals faced with this condition have valves in their lower 
extremity that are not functioning well and therefore they are unable to provide proper 
circulation throughout the limb as well as take blood from the extremity back to the heart 
(Mekkes et al. 2003). As a result, the capillaries are faced with increased tension in an effort to 
accommodate the increased blood supply in the area.  
If the situation is not treated, the capillaries become malformed and eventually become 
leaky. These leaky capillaries allow the movement of proteins that are usually fond in the plasma 
to enter the tissue resulting in protein-rich edema (Bollinger et al. 1997). This often leads to the 
formation of microthrombi blocking the capillaries and subsequently causing the build up of 
activated leukocytes to the area (Coleridge et al. 1988). This edema eventually leads to localized 
tissue hypoxia. Hypoxia in the presence of elevated levels of activated leukocytes can promote 
breakdown of tissue leading to the formation of a venous statis ulcer (Yager et al. 2002). These 
types of chronic wounds are initially treated with cleansing, removal of necrotic tissue and 
compression therapy to help assist with the poor circulation. While these treatments help control 
the situation, most patients require the placement of stents to provide long term assistance with 
circulation.  
 
Factors Involved in Chronic Wounds 
 It has been clearly illustrated that elevated proteolytic activity is associated with delayed 
healing, however there are other factors that are equally important – infection, age, disease and 
socioeconomic factors. When an individual is injured and the injury involves the breaking of the 
skin, there is always the possibility of the wound being invaded by microbes that are part of the 
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dermal floral (Bowler et al. 2001). This invasion only becomes a concern when the host’s 
defense system is unable to get rid of the bacteria resulting in colonization and subsequent 
infection of the wound. A study aimed at understanding the connection between healing and 
infection revealed that the exudate from pressure ulcers with a bacterial load greater than 106 
CFU/ml were faced with the problem of delayed healing (Bendy 1964).  A large number of types 
of bacteria have been implicated in the delayed healing seen with chronic wounds.  These 
include Gram positive bacteria such as Staphylococcus aureus and Gram-negative bacteria such 
as Pseudomona aeruginosa and Acinetobacter baumanni (Yun et al. 2006).  
 Nutrition and age also play a role in delaying the healing process. The older a person is, 
the more fragile their skin which not only makes them more susceptible to wounds, but the 
healing process is also slower (Marcus et al 2000). In addition studies have shown that there is 
decreased proliferation of fibroblasts and keratinocytes which are key players in the tissue 
formation stage (Ashcroft et al. 2002). There is a strong connection between one’s ability to heal 
and the amount of nutrition that person receives. The wound healing process is an energy 
intensive one that requires the synthesis and release of a host of proteins which can become a bit 
of a challenge for someone who is undernourished (Russell 2001; Williams et al. 2003).  
In addition, insufficient intake of carbohydrates and fat which are the primary source of 
energy results in the body relying on the protein catabolism as a source of energy leading to 
hyoproteinemia. Hypoproteinemia reduces the amount of amino acids available for the synthesis 
of new protein at the site of injury and it has been shown that insufficient levels of amino acids 
such as arginine can inhibit the body’s immune response (Barbul et al. 1990). Although proper 
nutrition is important, there is currently no standardized method to measure nutritional adequacy 
although serum albumin is often used as an indicator (Yager et al. 2002). Another contributing 
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factor to chronic wounds is diseases such as cancer and HIV in which the patient’s immune 
system is compromised (Lord 1997). A compromised immune system means it is difficult for the 
body to initiate the necessary immune response to ensure proper healing of the wound.    
 
Treatments: Dressings and Drugs 
 Given our understanding of chronic wounds and the various facets that contribute to its 
perpetuation, it is imperative that more effective treatments need to be developed to target the 
elevated levels of neutrophils and increased bacterial infection without adversely affecting the 
newly re-constructed tissue. Dressings are the most popular form of treatment because it is an 
effective way of closing off the wound to the environment in an attempt to limit further infection 
and encourage healing. Most dressings contain silver because of its potent antimicrobial activity. 
However, a universal dressing product cannot be used for all wounds, but it must be tailored 
based on the nature of the injury (Higgins et al. 1995). Last year, scientists at an Israeli lab 
developed a copper dressing that was designed to protect the wound from the elements as well as 
promote angiogenesis (Borkow et al. 2010). While this dressing was shown to work better than 
the traditional silver dressing, it does not address the problem of elevated levels of neutrophils.  
 Recently work by Moor, Gould and Vachon confirm that an anionic macromolecule, 
polysterene sulfonate (PSS) is able to inhibit elastase activity via electrostatic interactions 
rendering the enzyme inactive (Moor et al. 2009). In addition, to PSS several cations such as 
doxycyline, chlorhexidine, and silver have been implicated in promoting the healing process 
because of their strong antimicrobial potency.   
 Chlorhexidine gluconate is a cationic biguanide with a very broad spectrum of action 
against bacteria.  The antibacterial action of chlorhexidine is believed to be mediated by its 
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disruption of bacterial cell membranes (Mohammadi and Abbott, 2009).  The major membrane 
components of prokaryotic cells are phospholipids, and their membranes contain higher amounts 
of anionic lipids than eukaryotic cell membranes but no cholesterol or sphingomyelin 
(Mohammadi and Abbott, 2009).  Thus, it is likely that cationic biguanide-based antimicrobials 
will preferentially target bacteria over eukaryotic cells. At high concentrations chlorhexidine is 
bactericidal, at low concentrations it is bacteriostatic. 
 Doxycycline a member of the class of antibiotics referred to as tetracyclines and is one of 
the many bacteriostatic chemicals that are widely used in the medical field to treat infections. It 
can prevent bacterial growth by inhibiting protein synthesis in the organism. This is achieved by 
the chemical binding to the 30s ribosomal subunit in the mRNA translation complex. This 
interaction prevents the amino-acyl tRNA from binding to the A site of the ribosome (Vincente 
et al. 2010).  
 
Specific Aims 
It has been shown that chronic wounds are very complex to treat because there are many 
factors that contribute and perpetuate their existence. Although there are therapies and treatments 
available, many of them are not very effective at targeting the enzymes and proteases that are 
responsible for arresting the wound in the inflammatory stage. PSS was used as the backbone of 
these formulations because of its large structure and stable structure. The molecule contains an 
aromatic ring which is very difficult to break because of the strong pi-pi interactions of the 
carbon atoms. In addition, it has a strong negative charge which allows it to easily form ionic 
bonds with cations. The flexibility of this compound makes it a very versatile platform on which 
an array of charged molecules can be attached. The aim of this research is combine PSS, an 
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anionic macromolecule that has been shown to inhibit proteolytic activity in chronic wounds 
with cations that have an antimicrobial property and which may posses the ability to attenuate 
the activity of these degradative enzymes encouraging the injury to transition out of the 
inflammatory phase and progress towards the final stage of healing.  
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Materials and Methods 
 
Test Formulations 
Six formulations were developed and provided by IASIS Molecular Sciences, LLC, 
Spokane, Washington. These formulations included PSS and five salt derivatives of the anionic 
polymer namely: PSS-Calcium, PSS-Chlorhexidine, PSS-Doxycycline, PSS-Glutathione and 
PSS-Silver.  PSS-Doxycycline and PSS-Chlorhexidine were found to be poorly soluble in 
aqueous solution.  Stocks of these two formulations were made up in DMSO, while all of the 
other formulations were dissolved using distilled water to yield a working stock concentration of 
20mg/ml. 
 
Elastase Inhibition Assay 
 An elastase assay was designed to determine how well the formulations were able to 
inhibit elastase activity. This assay involved using an Elastase buffer [100mM Hepes (pH 7.5), 
500mM NaCl, 0.05% Triton X-100 and distilled water], DMSO, deionized water, an elastase-
specific substrate (Methoxysuccinyl-Ala-Ala-Pro-Val-paranitroanilide (Calibiochem, San Diego 
CA), the formulations and fluid obtained from a pressure ulcer using the VAC (vacuum-assisted 
closure) device with the approval of the Virginia Commonwealth University IRB.  
Comparison of the wound fluid against purified neutrophil elastase revealed a titer of 13 
units of elastase activity per ml (where one unit is defined as the amount of enzyme that will 
hydrolyze 1.0 µmol of MeO-Suc-Ala-Ala-Pro-Val-pNA per minute at 25ºC, pH 8.0).    
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Formulations were incubated in Elastase buffer containing 25mU/ml elastase.  Except where 
noted, formulations were used at a final concentration of 100µg/ml and typical reaction volumes 
were 500µl.  Reactions were incubated for one hour at room temperature (except where noted).   
 To measure elastase activity, 160µl aliquots were mixed with 40µl of the elastase 
substrate (600µM final concentration) and incubated at room temperature.  Cleavage of the 
substrate, as reflected by release of p-nitroaniline, was monitored spectrophotometrically at 
405nm at 60 second intervals for 10 minutes.   Standard curves were generated using the diluted 
wound fluid. Using the standard curve, the concentrations of elastase remaining in the wound 
was calculated.  All reactions including the standard curve were performed in duplicate. 
 
 Cathepsin G Assay 
 The ability of the PSS-formulations to inhibit cathepsin G was determined in a similar 
manner. This assay involved using the Elastase buffer, cathepsin G substrate (N-Succinyl-A-AP-
F-p-NA (Calibiochem, San Diego CA), the PSS formulations, and cathepsin G (MP 
Biochemicals: #191344, MW 23,500, 2-4 units/mg protein).  A working stock of enzyme was 
made by reconstituting the lyophilized enzyme (100µg) in 1ml of 50% glycerol-50m M sodium 
acetate-150m M NaCl pH 5.5 for a concentration of 100µg/ml or a minimum of 200 
milliunits/ml. 
Cathepsin G was diluted with buffer to 2.2 milliunits/ml and PSS-formulations to 2mg/ml 
in the same buffer.  Equal volumes (200µl) of enzyme and PSS-formulation were then mixed and 
incubated at room temperature for 1 hour.   
 To measure remaining cathepsin G activity, 160µl aliquots were mixed with 40µl of 
2mM cathepsin G substrate (400µM final concentration) and incubated at room temperature.  
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Cleavage of the substrate, as reflected by release of p-nitroaniline, was monitored 
spectrophotometrically at 405nm at 60 second intervals for 10 minutes.   Standard curves were 
generated using dilutions of cathepsin G.   Using the standard curve, the concentrations of 
cathepsin G activity remaining in the samples were calculated.  All reactions including the 
standard curve were performed in duplicate. 
 
Effects of PSS-Formulations on the Activity of Myeloperoxidase (MPO) 
 The ability of the PSS-formulations to inhibit myeloperoxidase was examined by 
adapting a standard assay.  In this assay, H2O2 is broken down by myeloperoxidase.  The oxygen 
radical that is produced combines with a hydrogen donor, o-dianisidine dihydrochloride (AH2) which is 
converted to a colored compound (A). 
(1) H2O2 → H2O + O- 
 
(2) O- + AH2 → H2O + A 
 
Neutrophil myeloperoxidase, 200 milliunits/ml, (EMD catalog # 475911) and 1mg/ml PSS-
formulation in a total volume of 240 µl of 50mM sodium phosphate, pH 6.0 were incubated at 
room temperature.  At 2 and 24 hrs, duplicate 50µl aliquots were removed and mixed with 50µl 
of 800µM o-dianisidine dihydrochloride and 50 µl of 0.01% hydrogen peroxide.  Dilutions of the 
myeloperoxidase incubated without a PSS-formulation were used to generate a standard curve.  
The reaction was followed by measuring the absorbance at 450nm every two minutes for twenty 
minutes.   
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Inhibition of Bacterial Growth by PSS-Salts 
 PSS-silver, PSS-doxycycline and PSS-chlorhexidine were tested for their ability to 
inhibit the growth of bacteria.  For this study, cultures of clinically relevant bacteria were 
obtained from the VCU Microbiology/Immunology Laboratory, Department of Clinical 
Pathology.  These bacteria, Pseudomonas aeruginosa, Acinetobacter baumanni and 
Staphylococcus aureus, are commonly associated with non-healing chronic wounds (Yun et. al 
2006).  Isolated colonies of the individual organisms were picked and used to generate stocks by 
growing overnight in 5 ml of Lysogeny Broth (LB) media  at 37°C at 200-300 RPM.    
The minimal inhibitory concentration-50 (MIC50) is defined as the minimal concentration 
of an agent that inhibits the growth of an organism 50%.  This is a standard means of assessing 
the effectiveness of antimicrobials.  PSS-formulations were serially diluted (typically two-fold) 
in quadruplicate in 48-well plates containing LB alone or LB containing 10% fetal calf serum.  
Overnight cultures of bacteria were diluted 1:1000 in LB and 20µl used to inoculate each well.  
The initial (T=0) light scattering at 600nm was determined to provide a baseline. The plate was 
then placed in a 37°C shaker (200 RPM) overnight and read again at 600nm the following day.  
 Growth as represented by mean (n=4) light scattering at 600nm was plotted as a function 
of the concentration of the PSS-formulation.  From this, the Minimum Inhibitory Concentration 
required to inhibit the growth of 50% (MIC50) of the three different bacteria was determined. 
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Cytotoxicity Assay 
 To assess cytotoxicity, human neonatal fibroblasts were seeded onto 88 wells of 96-well 
cell culture plates, 100µl/well, at a density of 5 x 104/ml.  After 24hr, the medium was replaced 
with 100µl of fresh medium containing graded concentrations of the PSS-formulations.  Half-log 
serial dilutions from 800 µg/ml to 13 ng/ml were made.  Four replicate wells per concentration 
were tested.  The plates were incubated overnight in a humidified atmosphere (5% CO2/95% air) 
at 37ºC.     
To quantify cell viability, the medium was replaced with fresh medium containing 5% 
CellTiter 96® AQueous One Solution Reagent (Promega Corp.).  This reagent contains a novel 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS).  The absorbances at 490nm were read (T=0) and the plates 
placed back in the incubator for 1 hr and then the absorbances read again. In this assay, the 
yellow tetrazolium salt is reduced by NADPH or NADH (produced by dehydrogenases) in viable 
cells to a soluble blue formazan product.  The change in absorbance that occurred in 1hr was 
then determined and plotted as a function of concentration.  The Inhibitory Concentration-50 
(IC50) value was defined as the concentration allowing 50% survival of cells and was determined 
graphically. 
 
Biocompatability Indices 
 For this study, the Biocompatibility Index of the investigated PSS-formulations was 
defined as the ratio of each formulation’s IC50 on human dermal fibroblasts and its mean MIC50.  
This yields a dimensionless value.  A Biocompataibility Index (BI) greater than 1.0 represents an 
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agent that preferentially targets microbes.  A BI of less than 1.0 would indicate that the agent is 
relatively cytotoxic.   
 
Data Analysis 
Except where noted, experiments were repeated a minimum of eight times.  Error bars represent 
one standard deviation. 
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Results 
 
Elastase Assay 
As previously stated, one of the aims of these studies was to test the hypothesis that 
various salts of the anionic polymer, polystyrene sulfonate (PSS), are able to modulate the 
activities of various neutrophil-derived cationic proteins.  Previous studies have shown that a 
characteristic feature of chronic wounds is the persistent elevated level of these proteins (Yager 
1999) hence it is imperative to not only understand the mechanism that triggers their over 
expression, but to find a way to decrease their levels.  In addition, salts in which the cation is a 
known antimicrobial were tested for their ability to inhibit the growth of bacteria that are 
commonly found in the chronic wound environment.   
 The first experiment was done to determine the effects the formulations had on elastase 
activity. This was achieved by using an elastase assay in which Methoxysuccinyl-Ala-Ala-Pro-
Val-para-nitroaniline was the substrate. This particular substrate is specific to elastase which is 
an important characteristic given the fact that for these experiments, wound fluid which has 
numerous proteases, served as the elastase source. As a prelude, a pilot assay was performed to 
test whether the wound fluid contained elastase activity and that para-nitroanaline was released 
in a linear dose response manner. As shown in Fig 1. para-nitroanaline was released in a linear 
dose-response.   
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Figure 1: Elastase Activity showing a change in absorbance with time  
 Each of the six PSS formulations were tested for their ability to inhibit elastase. 
Reactions contained 1.0mg/ml of PSS-formulations in a 240µl volume containing 25milliunits of 
elastase and were incubated for two hours at room temperature before measuring remaining 
activity. Elastase activity was measured kinetically measuring absorbance at 405nm. Typical 
results are shown in Figure 2 and are presented as the percentage of activity inhibited. With the 
exception of PSS-chlorhexidine, all the formulations efficiently inhibited elastase activity (≥ 
90%) and the formulations that had a cation attached to them were no more effective than the 
pure PSS which seems to suggest that none of the cations used significantly contributed to 
elastase inhibition in the wound fluid. Working stocks (20m/ml) of both the doxycycline and 
chlorhexidine PSS salts were made with DMSO. PSS-doxycycline remained in solution when 
  22
diluted to 1.0 mg/ml in the aqueous buffer.  In contrast, PSS-chlorhexidine formed a large 
precipitate when added to the aqueous buffer.   The compound’s inability to sufficiently dissolve 
may account for the relatively large error that was observed.  Nevertheless, this compound still 
managed ability to achieve approximately 30% elastase inhibition.  
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Fig. 2 Formulations were incubated with wound fluid for 1hr. at room temperature. Elastase 
activity was determined by incubating aliquots with the elastase-specific substrate, 
methoxysuccinyl-Ala-Ala-Pro-Val-paranitroanilide and measuring anilide release overtime. The 
maximum slope was compared to a standard in parallel. Elastase activity was greatly reduced by 
all of the formulations except PSS-Chlorohexidine 
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Given the fact that the results showed that PSS was able to inhibit elastase activity, 
further experiments were designed to examine the kinetics of this inhibition. To that end, a time 
response assay was done using the same protocol as the first experiment except changing the 
incubation duration to hourly increments. In so doing, one would be able to determine how long 
the elastase needed to be exposed to the formulations before it was inactivated. The results of 
this round of experimentation revealed that there was no increase in the level of inhibition after 
one hour (Figure 3A) which was indicative of the fact that the elastase inhibition was occurring 
much sooner than hypothesized.  
In order to capture the rate of inhibition, the time response assay was repeated, using 
10mins increments. (Figure 3B). The results showed that even without preincubating, efficient 
inhibition (>80%) was observed with maximum inhibition of 90.00% occurring after 20mins but 
subsequently declining to 80% inhibition. This experiment clearly demonstrated that the kinetics 
of the elastase-formulation interaction was relatively quick and maybe occurring within a matter 
of seconds of them meeting. It is worthy to note that the variability in the observed PSS 
inhibition in latter experiment vs. that of the previous experiments could be as a result of the 
progressive weakening in the potency of the formulations from the time stock solutions of them 
were made to the time they were used (all stock solutions were used within a week after which 
they were discarded). However, despite the lower inhibitory activity observed in the later 
experiments in which PSS was the only formulation used, the effect was still significant >80%.  
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Elastase Inhibition with PSS: 10mins. Time Course
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Figure 3. Elastase inhibition: time course. PSS was incubated at room temperature with wound 
fluid for varying times: (A) hour segments, (B) mins. segments. Elastase activity was determined 
by incubating aliquots with the elastase-specific substrate, methoxysuccinyl-Ala-Ala-Pro-Val-
paranitroaniline and measuring aniline release overtime. The maximum slope was compared to a 
standard in parallel. Elastase activity was greatly reduced after 20 mins, however approximately 
16% of elastase activity was regained after 10mins. 
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With the initial set of experiments not only confirming that PSS was able to inhibit 
elastase activity, but it was able to do so after a relatively short period of time, further research 
was done in the form a dose response assay. In so doing, the results of the assay would help 
determine the minimum amount of the PSS formulation that would be needed to inactivate the 
elastase. This experiment was important if future work was going to be done to develop a 
treatment method that would incorporate these formulations into at a concentration that would be 
potent enough to inhibit elastase activity without damaging surrounding, healthy tissue. In this 
assay, the PSS formulation was serially diluted (1 log dilutions) in order to determine the 
minimum concentration of the salt that was needed to inhibit the elastase. The results revealed 
that as little as 0.1microgram of PSS was able to inhibit 82% of elastase activity (Figure 4) using 
these reaction conditions.  
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Figure 4. Elastase inhibition: PSS dose response. Varying doses of PSS was incubated at room 
temperature with wound fluid. Elastase activity was determined by incubating aliquots with the 
elastase-specific substrate, methoxysuccinyl-Ala-Ala-Pro-Val-paranitroanilide and measuring 
anilide release overtime. Percent inhibition was determined by comparing remaining activity 
with a standard curve.  
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 Although the results that were obtained up to this point in the project was very reassuring, 
questions were raised regarding the interaction between the formulation and the elastase. Before 
progressing further with the effectiveness of the formulations to inhibit other proteases and 
microbial activity, it was necessary to validate that the observed inhibition was as a result of the 
formulation binding to the elastase and not the elastase substrate. In the event, the formulation 
was in fact inhibiting the substrate, then the elastase inhibition observed was not really 
inactivation of the protease but it was a ‘sequestering’ of the substrate so that it was no longer 
available to the elastase.  To address this, 40ul of the substrate (600uM) was mixed with 160ul of 
1mg/ml PSS.  This mixture was immediately centrifuged at 15k x g for 30 minutes through a 
Microcon centrifugal filter unit YM-10 membrane with a 10 kDa cutoff.  This membrane would 
retain the 70 kDa PSS molecule and any substrate that bound to it.  Unbound substrate that 
passed through (smaller than 10 kDa) was then mixed with 25 milliunits of elastase and the 
release of paranitroanilide monitored at 405nm.  This was compared to substrate not mixed with 
PSS but also passed through a filter.  There was no significant difference in the amount of 
paranitroanilide that was released.   This indicates that the observed reduction in activity was due 
to interactions of PSS with neutrophil elastase and not to protection of the substrate by the PSS 
molecule. 
 
Cathepsin G Assay 
Prior studies have shown that like elastase, cathepsin G was another cationic neutrophil-
derived serine protease whose levels are elevated in chronic wounds (Yager 1999). Therefore, 
reducing the proteolytic activity of this enzyme would help the chronic wound progress pass the 
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inflammatory stage. To that end, the various formulations were added to a working stock of 
100µg/ml of purified cathepsin G.  The enzyme stock solution was further diluted with buffer to 
yield a final concentration of 2.2milliunits/ml. It was then incubated with 2mg/ml of the 
formulations at room temperature for an hour. The results of the cathepsin G assay showed that 
all of the formulations were able to inhibit >90% of cathepsin G activity, with PSS-
chlorohexidine and doxycycline providing complete inhibition of the protease. (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Purified cathepsin G was incubated for an hour at room temperature with each of the 
six formulations and then percent inhibition was determined. 
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Myeloperoxidase Assay 
Myeloperoxidase (MPO) is one of the many proteins that are found in the intracellular 
granules of neutrophils and it is often used as a marker to quantify the degree of inflammation 
and estimate the accumulation of neutrophils in tissues. Five percent of the total protein of a 
neutrophil is comprised of MPO.  The principal reaction mediated by MPO uses H2O2 and Cl- as 
substrates to generate hypochlorous acid which is subsequently metabolized to hypochlorite and 
chlorine: 
H2O2 + Cl- + H+ → H2O + HOCl 
HOCl  ↔ H+ OCl- 
HOCl + Cl- +→ Cl2 + OH— 
  It has been hypothesized that elevated levels of MPO with the subsequent production of 
large amounts of highly reactive oxidants in chronic wounds can severely impair the wound’s 
ability to heal. MPO is a cationic protein, therefore, the PSS formulations were tested for their 
ability to inhibit MPO.  A MPO assay similar to the previous assays was designed to monitor the 
protein’s activity. In this assay 200 milliunits/ml of MPO was incubated for two hours and 24 
hours with 1mg/ml of the PSS-formulations. Oxidation of o-dianisidine dihydrochloride when 
H2O2 was provided was then determined.  The absorbance of the reaction was measured every 
two minutes for twenty minutes and the results showed that the only formulation that was able to 
inhibit MPO activity was PSS-Glutathione while the other formulations appeared to increase the 
apparent activity of MPO (Figure 6).  
The results of this experiment clearly illustrate that PSS and most of the PSS 
formulations were unable to reduce the enzymatic activity of MPO.  Further reviewing of the 
literature revealed evidence that glutathione can react directly with H2O2. As a result, what 
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seemed to be a reduction in MPO activity was more likely a case of substrate depletion.    In 
contrast, several of the other PSS-formulations appeared to “increase” MPO activity.  The 
reasons for this remain unclear.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Myeloperoxidase Inhibition after 24hr. incubation with the formulations. Values greater 
than zero indicate increased activity and values less than zero are indicative of inhibition.  
 
Bacterial Inhibition 
 Another important aspect of chronic wound pathology is infection.  A large number of 
bacteria species have been observed in chronic wounds.  Infection can impair healing either 
directly through the actions of bacterial products (e.g., endotoxins), or indirectly through the 
provoking of an exuberant inflammatory response.  Thus, approaches targeting the microbial 
flora is an attractive strategy for treating these problem wounds.  Several of the PSS-
formulations have been designed with antimicrobials as the cation.  The ability of these 
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formulations to inhibit planktonic bacterial growth was investigated.  For this purpose, these 
formulations were tested against three clinically isolated bacteria that are commonly associated 
with non-healing chronic wounds namely Pseudomonas aeruginosa, Acinetobacter baumanni 
and Staphylococcus aureus. The bacteria were grown in LB media as well as LB media and 10% 
fetal calf serum as a means to mimic the physiological environment of the wound.  The microbes 
were incubated overnight with serial dilutions of some of the formulations that contained a cation 
with known antimicrobial property PSS-chlorhexidine and PSS-doxycycline and resulting 
growth was plotted as a function of the concentration of the formulations.  
A representative result of the data obtained is shown in Figure 7. Further analysis of the 
data from this experiment was done in an effort to calculate MIC50: the concentration of the PSS 
formulations at which 50% of the microbial growth was inhibited (Table 1).  Surprisingly, 
especially in the case of PSS-silver, presence of serum in the LB had a negligible influence on 
the observed MIC50s.  Because silver ions react fairly non-specifically with targets such as thiols, 
it was expected that the presence of additional organic material in the medium would reduce its 
effectiveness. 
There was some interest regarding whether interactions of PSS with the antimicrobial 
cations might influence their effectiveness.  To examine this, the ability of PSS-doxycycline to 
inhibit the growth of Staph. aureus was compared with doxycycline alone.  Based on a weight-
mass comparison, the MIC50 for PSS-doxycycline was indeed slightly higher than that observed 
for doxycycline alone.  This slight difference might be attributed to the slightly lower 
concentration of doxycycline in the PSS-doxycycline reactions.    
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Figure 7 Representative MIC50 of Acinetobacter baumanni and PSS-chlorhexidine. Bacteria 
were grown in LB media or LB media + 10% fetal calf serum containing serial dilutions of PSS-
chlorhexidine or PSS-doxycycline. Growth was monitored by mean light scattering at 600nm 
and plotted as a function of the concentration of the PSS-formulation 
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Table 1 Growth Inhibition of Clinically Relevant Bacteria 
  MIC50 
Bacteria Formulation LB Media  LB Media + 10% FCS 
Acinetobacter baumanni PSS-chlorhexidine 50 mcg/ml 105 mcg/ml 
 PSS-doxycycline 0.3 mcg/ml 12 mcg/ml 
 PSS-silver 3.0mcg/ml 4.0mcg/ml 
    
Pseudomonas aeruginosa PSS-chlorhexidine 105 mcg/ml 108 mcg/ml 
 PSS-doxycycline 70 mcg/ml 80 mcg/ml 
 PSS-silver 2.0mcg/ml 6.0mcg/ml 
    
Staphylococus aureus PSS-chlorhexidine 9 mcg/ml 80 mcg/ml 
 PSS-doxycycline 0.2 mcg/ml 0.6 mcg/ml 
 PSS-silver 8.0 mcg/ml 9.5 mcg/ml 
 
Cytotoxicity 
 Although relatively low concentrations of the formulations were needed in order to kill 
the microbes, further work needed to be done to determine whether these concentrations were 
also harmful to eukaryotic cells. To that end, a cytotoxicity assay was performed using human 
neonatal dermal fibroblasts as a source of eukaryotic cells. The fibroblasts were incubated 
overnight with serial dilutions of the formulations.  Viability was then assessed by measuring the 
conversion of MTS into formazan. Plotting formazan production (reflection of viable 
mitochondria) as a function of formulation concentration allowed the determination of the 
Inhibitory Concentration (IC50) i.e. the concentration of the formulation that killed 50% of the 
cells (Table 2).  
 
Table 2: Cell Viability Post Treatment 
Formulations IC50 
PSS >1000 mcg/ml 
PSS-calcium >1000 mcg/ml 
PSS-chlorhexidine 20 mcg/ml 
PSS-doxycycline >1000 mcg/ml 
PSS-gluathione >1000 mcg/ml 
PSS-silver 20 mcg/ml 
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Compatibility Index 
 Compatibility indices are very useful tools in figuring out whether or not it would be in 
the best interest of the patient to administer a new drug. It is calculated by dividing the IC50 by 
the MIC50 and if the resulting number is greater than 1, it means that the treatment in question 
would kill the microbe causing negligible damage to healthy tissue. On the other hand, if the 
resulting number is less than 1, it means that the concentration of the drug needed to destroy the 
microbe is high enough to kill healthy cells.  
 From the analysis conducted, PSS-doxycycline and PSS-silver consistently had a 
compatability indices value greater than 1 (Table 3) suggesting that they were the best treatment 
options if the formulations were to be incorporated in a product.  
The results of the various assays were very promising as they all, except for the MPO 
experiment, showed that they were able to inhibit the various neutrophilic proteases with which 
they were incubated. In addition, the results clearly illustrated the multidimensionality of the 
anionic macromolecule PSS because one can now make a formulation that contains the PSS with 
various cations attached to it in order to combat the elevated proteolytic environment by 
simultaneously targeting a wide variety of enzymes.  
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Table 3: Compatibility Index   
  Compatibility Index 
Bacteria Formulation LB Media  LB Media + 10% FCS 
Acinetobacter baumanni PSS-chlorhexidine 0.400 0.190 
 PSS-doxycycline 3333.333 83.33 
 PSS-silver 6.666 5.0 
    
Pseudomonas aeruginosa PSS-chlorhexidine 0.190 0.185 
 PSS-doxycycline 14.286 12.500 
 PSS-silver 10.0 3.333 
    
Staphylococus aureus PSS-chlorhexidine 2.222 0.250 
 PSS-doxycycline 5000 1666.667 
 PSS-silver 2.5 2.105 
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Discussion 
Chronic wounds are a growing concern because their treatment represents a significant 
healthcare cost and with the growing age of the population, it is a problem that will continue to 
grow. To that end, it is imperative that cost-effective therapies be developed to adequately 
resolve this problem.  This study examined the ability of PSS-formulations to inhibit two 
different serine proteases that are primarily neutrophil-derived and their ability to inhibit 
myeloperoxidase.  In addition, the ability of three of these formulations to inhibit bacterial 
growth and to what extent they demonstrated cytotoxicity towards human dermal fibroblasts was 
examined. 
The results of study confirmed that PSS was able to inhibit the activity of the cationic 
serine protease, elastase, (>90%) and the various salt derivatives were just as effective as the 
anionic macromolecule to which they were attached.  One can therefore infer that the cations that 
were added to the anionic PSS macromolecular anion were not binding to the PSS in a way that 
prevented it from interacting with elastase that were examined or they themselves were not 
contributing to the overall protease inhibition. This finding confirmed the work by Sorsa that 
showed that while tetracyclines like doxycycline were effective at inhibiting MMPs, another 
neutrophilic protease, the chemical had no effect on elastase activity (Sorsa 1994). It remains to 
be seen whether PSS by itself or in combination with doxycycline can also inhibit MMPS, in 
particular, MMP-8 or MMP-9.  Both of these MMPs are expressed primarily by neutrophils.   
It was also shown that a relatively low concentration of the formulations was needed and 
the observed inhibition happened shortly after the protease was exposed to the salts. The fast 
acting inhibition is an encouraging sign because it means that if any of these formulations were 
to be added to a chronic wound, it can quickly attenuate the destructive activity of the enzyme.  
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The formulations were also able to reduce the activity of Cathepsin G, another cationic 
serine protease whose levels are elevated in chronic wounds. In the case of cathepsin G, there 
were two formulations namely PSS-chlorhexidine and PSS-doxycycline that were more effective 
than the other salts, which provided >85% inhibition. There was nothing found in the literature 
that explained or proposed the possible interaction between the protein and the cations that 
would cause them to be more effective than the other agents.  
In retrospect, the studies examining myeloperoxidase inhibition probably suffered with a 
design flaw. It was observed that PSS-glutathione was the only formulation that seemed able to 
inhibit the activity of the enzyme.  The ability of glutathione to directly inactivate hydrogen 
peroxide essentially interfered with the intended purpose of this assay.  However, some solace 
can be gleaned from the implied ability of PSS-glutathione to act as an antioxidant.  Another 
interesting observation was the apparent increase in MPO activity observed with several of the 
PSS-formulations.  There are several potential explanations that could explain this unusual 
observation. Firstly, the enhanced enzyme activity observed can be as a result of the PSS binding 
to the enzyme and stabilizing it.  Alternatively, PSS-myeloperoxidase complexes may conduct 
subtle changes in the myeloperoxidase protein making it efficient at substrate utilization/product 
synthesis.  It should be noted that the serine proteases targeted in this study act primarily as 
monomers.  In contrast, the 150-kDa myeloperoxidase protein is a dimer consisting of two 15-
kDa light chains and two variable-weight glycosylated heavy chains bound to a prosthetic heme 
group.  Such a complex structure may make access of the 70 kDa PSS molecule to the active site 
difficult (assuming that that is the operative mechanism for inhibition).  
Molecular modeling of the serine proteases and identification of the various binding sites 
on the enzymes would better help researchers understand the manner in which they interact with 
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PSS. It will also be helpful because maybe PSS is not an effective tool in shutting down the 
enzyme’s activity but knowing the structure of the enzyme may help researchers use a suitable 
substitute for PSS that can bind to the active site. 
Infection is another key feature of the chronic wound that often must be taken into 
consideration when managing the injury. Bacterial infection contributes to the severity of the 
wound because in addition to releasing toxins that can damage tissue, it also helps propagate the 
arrival of the phagocytic neutrophils, the cell responsible for the elevated protease levels. 
Therefore, it would be in the best interest of the patient to reduce and subsequently eliminate the 
presence of bacteria in the wound. To that end, the formulations were added to bacterial cultures 
to determine whether or not they were able to inhibit microbial growth of three bacteria 
commonly associated with chronic wounds namely Acinetobacter baumanni, Pseudomonas 
aerugionosa and Staphylococcus aureus. It is worthy to note that only two formulations with 
cations that have a known antimicrobial property were used in these set of experiments – PSS-
chlorhexidine, PSS-doxycycline. All of the formulations were able to inhibit microbial growth 
and their respective MIC50s were calculated.  At least in the case of doxycycline, complexing 
with PSS did not significantly diminish or increase antimicrobial effectiveness. 
Relatively low concentrations (in the microgram range) of the formulations were needed 
to prevent the growth of the bacteria, which is important because you want to be able to stop the 
bacterial growth while minimizing potential toxicity.  To this end, further experiments were done 
to see whether the concentration of the formulations used was strong enough to prevent bacterial 
growth but not damage the cells specifically fibroblasts. The results from these experiments were 
used to calculate the IC50 and combined with the MIC50 to generate a biocompatibility index of 
the various formulations. This information can be particularly useful when developing a 
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treatment because one would be able to figure out the maximum concentration of the drug that 
can be used without potentially damaging healthy tissue.  It is recognized that other cell types are 
also present in wounds and they may differ in their sensitivity to these formulations.  Of 
particular note is keratinocytes.  These cells are responsible for generating the epithelium and 
would perhaps have more contact with topical PSS-formulations than any other cell type.  Future 
studies could also determine biocompatibility for these cells. 
In summary, in recognition of the need for improved strategies for treating chronic 
wounds, this study examined the potential of a polyanionic molecule to serve as a platform that 
could affect multiple targets within a wound.  Experiments confirmed PSS’s ability to inhibit the 
activity of two serine proteases even when complexed with various cations.   Addition of cations 
such as doxycycline, tetracycline and silver generated formulations with the additional ability to 
act as antimicrobials.  Although very tentative, PSS-glutathione may act as an effective 
antioxidant. Importantly, none of these formulations demonstrate unacceptable toxicity to cells 
likely to be found at a wound site. The multidimensionality of the formulations would make it 
easy for one to custom design dressings depending on the severity and complexity of the wound 
environment. The fact that PSS all ready has FDA approval for oral use should also make this a 
relatively easy process to take this product from bench to clinic.  
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